ClinicalTrials.gg

Program

mezigdomide

Also written as “CC-92480”, “Mezigdomide” and “Cohort B1 & B2: KTX-1001+Mezigdomide”.

Its studies are mostly in Multiple Myeloma · Kidney Failure, Chronic, led by 2 companies.

Furthest: phase 3, since Aug 25, 202212 company-led studies, 4 open or runningNext primary completion: Jan 10, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb113 open or runningphase 3since Aug 25, 2022Dec 1, 2017Jan 10, 2027phase 3 · NCT05519085
K36 Therapeutics11 open or runningphase 1since Dec 1, 2022Dec 1, 2022Dec 31, 2027phase 1 · NCT05651932
  • Named in Bristol-Myers Squibb’s own pipeline as mezigdomide, phase 4, as of Oct 29, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 1, 2017First study: phase 2 study in Multiple MyelomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT03374085 · 200 enrolled · United States, Australia, Belgium and more
  2. Dec 17, 2018Phase 1 study in Healthy VolunteerBristol-Myers Squibb · NCT03803644 · 56 enrolled · United States
  3. Dec 24, 2019Phase 1 study in Healthy VolunteerBristol-Myers Squibb · NCT04211545 · 24 enrolled · United States
  4. Sep 21, 2020Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT04560738 · 8 enrolled · United States
  5. Apr 7, 2021Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT04839809 · 40 enrolled · United States
  6. May 20, 2022Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT05389722 · 24 enrolled · United States
  7. Aug 25, 2022Phase 3 study in RecurrenceBristol-Myers Squibb · NCT05519085 · 810 planned · United States, Argentina, Australia and more
  8. Sep 21, 2022Phase 3 study in RecurrenceBristol-Myers Squibb · NCT05552976 · 606 enrolled · United States, Argentina, Australia and more
  9. Dec 1, 2022K36 Therapeutics's first study: phase 1 study in Multiple MyelomaNew to K36 TherapeuticsK36 Therapeutics · NCT05651932 · 165 planned · United States, Canada, France and more
  10. Jan 23, 2023Phase 1 study in Hepatic ImpairmentBristol-Myers Squibb · NCT05707390 · 32 enrolled · United States
  11. Mar 12, 2024Phase 1 study in Renal InsufficiencyBristol-Myers Squibb · NCT06318676 · 26 enrolled · United States
  12. May 16, 2025Phase 2 study in Multiple MyelomaBristol-Myers Squibb · NCT06988488 · 62 planned · United States, Canada, China and more

Ahead

  1. Jan 10, 2027Primary completion: phase 3 study in RecurrenceBristol-Myers Squibb · NCT05519085
  2. May 31, 2027Primary completion: phase 2 study in Multiple MyelomaBristol-Myers Squibb · NCT06988488
  3. Dec 31, 2027Primary completion: phase 1 study in Multiple MyelomaK36 Therapeutics · NCT05651932

TargetBeta

“A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, mezigdomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and target…”NCIt, read by Claude

Other programs on CRBN

ProgramCompanyFurthest phaseStudies
LenalidomideruleBristol-Myers Squibbphase 4109
pomalidomideruleBristol-Myers Squibbphase 451
golcadomideBristol-Myers Squibbphase 311
Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506Bristol-Myers Squibbphase 11
HRS-3738Jiangsu HengRui Medicinephase 11

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06988488Multiple Myeloma · United States, Canada, China and more2RecruitingBristol-Myers SquibbMay 31, 202762
NCT06318676Renal Insufficiency · United States1CompletedBristol-Myers SquibbNov 15, 202426
NCT05707390Hepatic Impairment · United States1CompletedBristol-Myers SquibbSep 13, 202332
NCT05651932Multiple Myeloma · United States, Canada, France and more1RecruitingK36 TherapeuticsDec 31, 2027165
NCT05552976Recurrence · United States, Argentina, Australia and more3Active, not recruitingBristol-Myers SquibbSep 28, 2026606
NCT05519085Recurrence · United States, Argentina, Australia and more3RecruitingBristol-Myers SquibbJan 10, 2027810
NCT05389722Healthy Volunteers · United States1CompletedBristol-Myers SquibbNov 12, 202224
NCT04839809Healthy Volunteers · United States1CompletedBristol-Myers SquibbOct 8, 202140
NCT04560738Healthy Volunteers · United States1CompletedBristol-Myers SquibbMay 13, 20218
NCT04211545Healthy Volunteer · United States1CompletedBristol-Myers SquibbDec 26, 201924
NCT03803644Healthy Volunteer · United States1CompletedBristol-Myers SquibbMay 28, 201956
NCT03374085Multiple Myeloma · United States, Australia, Belgium and more2TerminatedBristol-Myers SquibbAug 20, 2025200

How it is read

Names in the registry

  • “CC-92480”, 6 entries
  • “Mezigdomide”, 4 entries
  • “mezigdomide”, 1 entry
  • “Cohort B1 & B2: KTX-1001+Mezigdomide”, 1 entry
  • “[14C]-CC-92480”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.